Windlas Biotech Q3 FY24 Concall notes:
- Very upbeat commentary by management.
- Injectible facility to be commerialized by end of FY24 and scaleup in FY25.
- Current quarterly revs at 160 crs. Potential upto 600-750 Crs/quarter after all capex is commercialized.
- Growth is good in trade generics and CDMO business.
- CDMO business is picking pace. No lumpy revenue here.
- Want to grow quarter on quarter (QoQ). Shows consistency in growth.
- Growing faster than Pharma industry.
- Based in Dehradun. Focus on North Indian markets.
- Exports are currently slow.
- Positive on all 3 verticals- CDMO, Trade generics & exports.
- Focus on sustainable and efficient operations.
- Higher employee expenses, lowering of margins due to ESOP scheme.
- Schedule M impact is to seen across CDMO players, as non-compliant facilities will be under crackdown.
Subscribe To Our Free Newsletter |